JAK1 and acute lymphoblastic leukemia: An additional study revealed that both ruxolitinib, a JAK1/2 inhibitor, and venetoclax, a BCL2 inhibitor, were ineffective in vivo for treating T-ALL in a mouse model because of leukemia cell infiltration into the CNS135.